NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
Clinical Trials
63 trialsNCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06264921 2025-09-25
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 1 Terminated
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04870112 2025-04-17
SCope-D1
AstraZeneca
Phase 1 Terminated
NCT04101357 2025-03-18
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
BioNTech SE
Phase 1/2 Terminated
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT01898156 2024-04-25
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT03699956 2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3 Terminated
NCT04352413 2024-03-07
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Terminated
NCT03499678 2023-12-22
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
HKGepitherapeutics
Terminated
NCT04308785 2023-10-23
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT04106167 2023-09-21
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Terminated
NCT05027867 2023-08-16
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Phase 2 Terminated
NCT04590781 2023-04-20
DUET-1-02
Xencor, Inc.
Phase 1/2 Terminated
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT03773133 2022-09-13
SSTR2+
Ipsen
Phase 1/2 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT00286169 2022-04-12
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Sumitomo Pharma Co., Ltd.
Phase 3 Terminated
NCT04422210 2021-11-08
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Hoffmann-La Roche
Phase 1 Terminated
NCT03387332 2021-08-27
APG-1252 in Patients With SCLC or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated
NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01573338 2021-04-08
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Bayer
Phase 1/2 Terminated
NCT03516084 2020-12-21
A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Zai Lab (Hong Kong), Ltd.
Phase 3 Terminated
NCT03724253 2020-10-23
NeoFIND
Advanced Accelerator Applications
Phase 2 Terminated
NCT03116971 2020-09-16
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
EMD Serono
Phase 1 Terminated
NCT01859741 2020-09-09
PINNACLE
Mereo BioPharma
Phase 1/2 Terminated
NCT03026166 2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
Phase 1/2 Terminated
NCT03361228 2020-05-21
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT02819999 2020-03-12
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase 1 Terminated
NCT02034123 2019-12-06
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
GlaxoSmithKline
Phase 1 Terminated
NCT02109016 2019-07-29
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Clovis Oncology, Inc.
Phase 2 Terminated
NCT02367352 2019-06-26
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
Phase 1 Terminated
NCT01722292 2018-12-28
A Study of LY2940680 in Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT02500914 2018-10-05
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Stemcentrx
Phase 1 Terminated
NCT02161419 2018-06-25
CONCEPT-SCLC
Bayer
Phase 2 Terminated
NCT01237678 2018-01-18
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
ImmunoGen, Inc.
Phase 1/2 Terminated
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated